MA53516A1 - Cyclodextrine utilisée dans le traitement et la prévention de la bronchoconstriction en phase tardive de l'asthme provoqué par des allergènes. - Google Patents
Cyclodextrine utilisée dans le traitement et la prévention de la bronchoconstriction en phase tardive de l'asthme provoqué par des allergènes.Info
- Publication number
- MA53516A1 MA53516A1 MA53516A MA53516A MA53516A1 MA 53516 A1 MA53516 A1 MA 53516A1 MA 53516 A MA53516 A MA 53516A MA 53516 A MA53516 A MA 53516A MA 53516 A1 MA53516 A1 MA 53516A1
- Authority
- MA
- Morocco
- Prior art keywords
- prevention
- bronchoconstriction
- treatment
- allergen
- late phase
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Immunology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Une cyclodextrine inhalable destinée à être utilisée dans le traitement et la prévention de la bronchoconstriction en phase tardive de l'asthme provoqué par des allergènes est divulguée. L'utilisation d'une cyclodextrine dans le traitement et la prévention par inhalation de la bronchoconstriction tardive dans l'asthme allergique est également divulguée.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BE202005430 | 2020-06-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA53516A1 true MA53516A1 (fr) | 2022-04-29 |
Family
ID=72521354
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA53516A MA53516A1 (fr) | 2020-06-15 | 2021-06-09 | Cyclodextrine utilisée dans le traitement et la prévention de la bronchoconstriction en phase tardive de l'asthme provoqué par des allergènes. |
Country Status (3)
Country | Link |
---|---|
US (1) | US20210386668A1 (fr) |
BE (1) | BE1028268B1 (fr) |
MA (1) | MA53516A1 (fr) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ263084A (en) * | 1993-03-12 | 1997-08-22 | Arris Pharm Corp | Dipeptide derivatives, treatment of immunomediated inflammatory disorders |
EP1655034A1 (fr) * | 2004-10-10 | 2006-05-10 | Université de Liège | Utilisation d'un composé de cyclodextrine pour le traitement et la prévention des maladies inflammatoires bronchiques. |
US20080175887A1 (en) * | 2006-11-20 | 2008-07-24 | Lixiao Wang | Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs |
-
2021
- 2021-06-09 MA MA53516A patent/MA53516A1/fr unknown
- 2021-06-13 BE BE20215463A patent/BE1028268B1/fr active IP Right Grant
- 2021-06-15 US US17/347,683 patent/US20210386668A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
BE1028268B1 (fr) | 2021-12-02 |
US20210386668A1 (en) | 2021-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zhao et al. | Incidence and risk factors for post-ERCP pancreatitis in chronic pancreatitis | |
ATE477804T1 (de) | Verfahren zur behandlung von entzündlichen erkrankungen des verdauungstrakts mit topisch wirksamen kortikosteroiden | |
Nathan et al. | Mometasone furoate: efficacy and safety in moderate asthma compared with beclomethasone dipropionate | |
MA34002B1 (fr) | Thérapie antivirale | |
HUP0303340A2 (hu) | Eljárások gyulladásos vagy autoimmun rendellenességek megelőzésére vagy kezelésére integrin alfa-v-béta-3 antagonisták más profilaktikusan vagy terápiásan hatásos ágensekkel kombinált beadásával | |
US4486450A (en) | Method of treating psoriatic skin and composition | |
NO20051212D0 (no) | Ny kombinasjon av glukokortikoider og PDE-4 inhibitorer for behandling av luftveissykdommer, allergiske sykdommer, astma og COPD | |
MA53516A1 (fr) | Cyclodextrine utilisée dans le traitement et la prévention de la bronchoconstriction en phase tardive de l'asthme provoqué par des allergènes. | |
De Wet et al. | Pyoderma gangrenosum, acne, and suppurative hidradenitis syndrome in end-stage renal disease successfully treated with adalimumab | |
JP2002537245A5 (fr) | ||
De Smet et al. | Grip strength in patients with tennis elbow. Influence of elbow position | |
MA53482B1 (fr) | Thérapie d'infections par le papillomavirus humain à haut risque | |
Chalmers et al. | T2 Single nucleotide polymorphisms in the ficolin-2 gene predispose to Pseudomonas aeruginosa infection and disease severity in non-cystic fibrosis bronchiectasis | |
BE1030002A1 (fr) | Compositions inhalables comprenant un complexe de hpbcd et de budesonide ou ciclesonide pour le traitement ou la prevention d'une maladie virale respiratoire | |
Glassberg et al. | Cardiovascular events in phase 3 trials of pirfenidone in idiopathic pulmonary fibrosis (IPF) | |
CALLAWAY et al. | Pyogenic infections of skin: etiologic factor in acute glomerulonephritis of children | |
Gargi et al. | Tourniquet application in snake bite: are we aweare | |
Finnigan et al. | Efficacy and Tolerability of AXA1125, an Endogenous Metabolic Modulator Composition, in Fatigue-predominant Long COVID: A Randomized, Double-blind, Placebo-controlled Study | |
Spangler | Pyoderma gangrenosum in a patient with psoriatic arthritis. | |
Thokchom et al. | Pyoderma gangrenosum with Takayasu's arteritis: A rare association | |
Abrol et al. | Knowledge, attitude, and behavior in the prescription of topical steroid for dermatological disorders among medical practitioners | |
Aozasa et al. | Case of oral lichen planus treated successfully with irsogladine maleate | |
EP0095512B1 (fr) | Composition antipsoriatique | |
AlEid | e02 Cutaneous polyarteritis nodosa | |
Nisar | e03 ACTH reborn: modernising the evidence |